Johnson & Johnson annual total liabilities
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Total Liabilities Growth & History (JNJ)
Johnson & Johnson's total liabilities was $117.67B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $117.67B | $9.05B | +8.33% |
| 2024 | 2024-12-29 | $108.61B | $9.83B | +9.95% |
| 2023 | 2023-12-31 | $98.78B | −$11.79B | −10.66% |
| 2022 | 2023-01-01 | $110.57B | $2.58B | +2.39% |
| 2021 | 2022-01-02 | $108.00B | −$3.62B | −3.24% |
| 2020 | 2021-01-04 | $111.62B | $13.36B | +13.60% |
| 2019 | 2019-12-29 | $98.26B | $5.05B | +5.42% |
| 2018 | 2018-12-30 | $93.20B | −$3.94B | −4.06% |
| 2017 | 2017-12-31 | $97.14B | $26.35B | +37.23% |
| 2016 | 2017-01-01 | $70.79B | $8.53B | +13.70% |
| 2015 | 2016-01-03 | $62.26B | $1.66B | +2.73% |
| 2014 | 2014-12-28 | $60.61B | $1.98B | +3.37% |
| 2013 | 2013-12-29 | $58.63B | $2.11B | +3.73% |
| 2012 | 2012-12-30 | $56.52B | −$43.0M | −0.08% |
| 2011 | 2012-01-01 | $56.56B | $10.23B | +22.09% |
| 2010 | 2011-01-02 | $46.33B | $2.23B | +5.07% |
| 2009 | 2010-01-03 | $44.09B | $1.69B | +3.99% |
| 2008 | 2008-12-28 | $42.40B | — | — |
Johnson & Johnson quarterly total liabilities
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
As of Jan 3, 2021
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $116.09B | $1.17B | +1.02% |
| Q1 2026 | 2026-03-29 | $119.71B | $4.15B | +3.59% |
| Q4 2025 | 2025-12-28 | $117.67B | $9.05B | +8.33% |
| Q3 2025 | 2025-09-28 | $113.54B | $5.41B | +5.00% |
| Q2 2025 | 2025-06-29 | $114.92B | $5.37B | +4.90% |
| Q1 2025 | 2025-03-30 | $115.56B | $13.62B | +13.36% |
| Q4 2024 | 2024-12-29 | $108.61B | $9.83B | +9.95% |
| Q3 2024 | 2024-09-29 | $108.13B | $13.30B | +14.02% |
| Q2 2024 | 2024-06-30 | $109.55B | −$5.73B | −4.97% |
| Q1 2024 | 2024-03-31 | $101.95B | −$23.15B | −18.51% |
| Q4 2023 | 2023-12-31 | $98.78B | −$11.79B | −10.66% |
| Q3 2023 | 2023-10-01 | $94.83B | −$5.69B | −5.66% |
| Q2 2023 | 2023-07-02 | $115.28B | $13.91B | +13.72% |
| Q1 2023 | 2023-04-02 | $125.10B | $21.45B | +20.70% |
| Q4 2022 | 2023-01-01 | $110.57B | $2.58B | +2.39% |
| Q3 2022 | 2022-10-02 | $100.53B | −$8.43B | −7.74% |
| Q2 2022 | 2022-07-03 | $101.37B | −$5.49B | −5.14% |
| Q1 2022 | 2022-04-03 | $103.65B | −$3.08B | −2.88% |
| Q4 2021 | 2022-01-02 | $108.00B | — | — |
| Q3 2021 | 2021-10-03 | $108.96B | $2.74B | +2.58% |
| Q2 2021 | 2021-07-04 | $106.86B | $11.46B | +12.01% |
| Q1 2021 | 2021-04-04 | $106.72B | $13.00B | +13.87% |
| Q4 2020 | 2021-01-04 | $111.62B | $13.36B | +13.60% |
| As of Jan 3, 2021 | 2021-01-03 | $111.62B | $13.36B | +13.60% |
| Q3 2020 | 2020-09-27 | $106.22B | $8.91B | +9.16% |
| Q2 2020 | 2020-06-28 | $95.40B | $1.07B | +1.13% |
| Q1 2020 | 2020-03-29 | $93.72B | $2.65B | +2.91% |
| Q4 2019 | 2019-12-29 | $98.26B | $5.05B | +5.42% |
| Q3 2019 | 2019-09-29 | $97.31B | $6.23B | +6.84% |
| Q2 2019 | 2019-06-30 | $94.33B | $1.86B | +2.01% |
| Q1 2019 | 2019-03-31 | $91.07B | −$2.30B | −2.46% |
| Q4 2018 | 2018-12-30 | $93.20B | −$3.94B | −4.06% |
| Q3 2018 | 2018-09-30 | $91.08B | $9.40B | +11.51% |
| Q2 2018 | 2018-07-01 | $92.48B | $11.59B | +14.33% |
| Q1 2018 | 2018-04-01 | $93.37B | $18.79B | +25.20% |
| Q4 2017 | 2017-12-31 | $97.14B | $26.35B | +37.23% |
| Q3 2017 | 2017-10-01 | $81.68B | $14.08B | +20.83% |
| Q2 2017 | 2017-07-02 | $80.89B | $13.54B | +20.11% |
| Q1 2017 | 2017-04-02 | $74.58B | $10.99B | +17.29% |
| Q4 2016 | 2017-01-01 | $70.79B | $8.53B | +13.70% |
| Q3 2016 | 2016-10-02 | $67.60B | $5.89B | +9.54% |
| Q2 2016 | 2016-07-03 | $67.34B | $6.44B | +10.57% |
| Q1 2016 | 2016-04-03 | $63.58B | $2.87B | +4.73% |
| Q4 2015 | 2016-01-03 | $62.26B | $1.66B | +2.73% |
| Q3 2015 | 2015-09-27 | $61.71B | $6.21B | +11.18% |
| Q2 2015 | 2015-06-28 | $60.91B | $3.75B | +6.57% |
| Q1 2015 | 2015-03-29 | $60.71B | $3.96B | +6.99% |
| Q4 2014 | 2014-12-28 | $60.61B | $1.98B | +3.37% |
| Q3 2014 | 2014-09-28 | $55.51B | −$1.62B | −2.84% |
| Q2 2014 | 2014-06-29 | $57.15B | $2.49B | +4.56% |
| Q1 2014 | 2014-03-30 | $56.75B | $2.07B | +3.78% |
| Q4 2013 | 2013-12-29 | $58.63B | $2.11B | +3.73% |
| Q3 2013 | 2013-09-29 | $57.13B | $1.94B | +3.51% |
| Q2 2013 | 2013-06-30 | $54.66B | −$656.0M | −1.19% |
| Q1 2013 | 2013-03-31 | $54.68B | −$147.0M | −0.27% |
| Q4 2012 | 2012-12-30 | $56.52B | −$43.0M | −0.08% |
| Q3 2012 | 2012-09-30 | $55.19B | $4.90B | +9.73% |
| Q2 2012 | 2012-07-01 | $55.32B | $5.33B | +10.67% |
| Q1 2012 | 2012-04-01 | $54.83B | $6.54B | +13.55% |
| Q4 2011 | 2012-01-01 | $56.56B | $10.23B | +22.09% |
| Q3 2011 | 2011-10-02 | $50.29B | $9.34B | +22.80% |
| Q2 2011 | 2011-07-03 | $49.98B | $10.53B | +26.70% |
| Q1 2011 | 2011-04-03 | $48.29B | $7.76B | +19.15% |
| Q4 2010 | 2011-01-02 | $46.33B | $2.23B | +5.07% |
| Q3 2010 | 2010-10-03 | $40.96B | −$218.0M | −0.53% |
| Q2 2010 | 2010-07-04 | $39.45B | −$1.74B | −4.23% |
| Q1 2010 | 2010-04-04 | $40.53B | — | — |
| Q4 2009 | 2010-01-03 | $44.09B | $1.69B | +3.99% |
| Q3 2009 | 2009-09-27 | $41.17B | — | — |
| Q2 2009 | 2009-06-28 | $41.19B | — | — |
| Q4 2008 | 2008-12-28 | $42.40B | — | — |
Johnson & Johnson total liabilities trends
Over the last five fiscal years, Johnson & Johnson's total liabilities increased from $111.62B to $117.67B, a change of $6.05B. The latest reported quarter, Q2 2026, shows $116.09B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
